Extracellular matrix as a contextual determinant of transforming growth factor-b signaling in epithelial-mesenchymal transition and in cancer http://www.tandfonline.com/doi/pdf/10.4161/19336918.2014.972788

Cell Adhesion and Migration

Volumn 8, Issue 6, 2014, Pages 588-594

  Cichon, Magdalena A ^a   Radisky, Derek C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer; EMT; Extracellular matrix; Fibrosis; Integrins; TGFb

Indexed keywords

INTEGRIN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; BREAST METASTASIS; CANCER THERAPY; CELL INVASION; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GLIOMA; HUMAN; IMMUNOSURVEILLANCE; MELANOMA; NEOPLASM; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION; CELL DIFFERENTIATION; CYTOSKELETON; EPITHELIUM CELL; METABOLISM; PHYSIOLOGY;

CELL DIFFERENTIATION; CYTOSKELETON; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMANS; INTEGRINS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84921803186     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/19336918.2014.972788     Document Type: Review

References (89)

1. Hynes RO, Naba A. Overview of the matrisome-an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 2012; 4: a004903; PMID:21937732; http://dx.doi.org/10.1101/cshperspect.a004903
2. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 2011; 209:139-51; PMID: 21307119; http://dx.doi.org/10.1530/JOE-10-0377
3. Radisky D, Muschler J, Bissell MJ. Order and disorder: the role of extracellular matrix in epithelial cancer. Cancer Invest 2002; 20:139-53; PMID:11852996; http://dx.doi.org/10.1081/CNV-120000374
4. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011; 3: pii: a005058; PMID: 21917992
5. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21:309-22; PMID:22439926; http://dx.doi.org/10.1016/j.ccr.2012.02.022
6. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010; 11:97-105; PMID:20075988; http://dx.doi.org/10.1038/embor.2009.276
7. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010; 339:269-80; PMID:19693543; http://dx.doi.org/10.1007/s00441-009-0834-6
8. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10:9-22; PMID:20029421; http://dx.doi.org/10.1038/nrc2748
9. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285:1028-32; PMID:10446041; http://dx.doi.org/10.1126/science.285.5430.1028
10. Glukhova MA, Streuli CH. How integrins control breast biology. Curr Opin Cell Biol 2013; 25:633-41; PMID:23886475; http://dx.doi.org/10.1016/j.ceb.2013.06.010
11. Ross TD, Coon BG, Yun S, Baeyens N, Tanaka K, Ouyang M, Schwartz MA. Integrins inmechanotransduction. Curr Opin Cell Biol 2013; 25:613-8; PMID: 23797029; http://dx.doi.org/10.1016/j.ceb.2013.05.006
12. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113:685-700; PMID:12809600; http://dx.doi.org/10.1016/S0092-8674(03)00432-X
13. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012; 13:616-30; PMID:22992590; http://dx.doi.org/10.1038/nrm3434
14. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003; 11:915-26; PMID:12718878; http://dx.doi.org/10.1016/S1097-2765(03)00109-6
15. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massague J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008; 133:66-77; PMID:18394990; http://dx.doi.org/10.1016/j.cell.2008.01.046
16. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res 2012; 347:11-20; PMID:21701805; http://dx.doi.org/10.1007/s00441-011-1201-y
17. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19:128-39; PMID:19114990; http://dx.doi.org/10.1038/cr.2008.328
18. Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 2007; 67:3752-8; PMID:17440088; http://dx.doi.org/10.1158/0008-5472.CAN-06-3851
19. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM, Derynck R. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 2007; 26:3957-67; PMID:17673906; http://dx.doi.org/10.1038/sj.emboj.7601818
20. Cipriano R, Kan CE, Graham J, Danielpour D, Stampfer M, Jackson MW. TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci U S A 2011; 108:8668-73; PMID:21555587; http://dx.doi.org/10.1073/pnas.1015022108
21. Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH, ten Dijke P. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J Biol Chem 2003; 278:3751-61; PMID:12446693; http://dx.doi.org/10.1074/jbc.M208258200
22. Yu L, Hebert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGFbeta responses. EMBO J 2002; 21:3749-59; PMID:12110587; http://dx.doi.org/10.1093/emboj/cdf366
23. Martin-Garrido A, Brown DI, Lyle AN, Dikalova A, Seidel-Rogol B, Lassegue B, San Martn A, Griendling KK. NADPH oxidase 4 mediates TGF-beta-induced smooth muscle alpha-actin via p38MAPK and serum response factor. Free Radic Biol Med 2011; 50:354-62; PMID:21074607; http://dx.doi.org/10.1016/j. freeradbiomed.2010.11.007
24. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoAdependent mechanism. Mol Biol Cell 2001; 12:27-36; PMID:11160820; http://dx.doi.org/10.1091/mbc.12.1.27
25. Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002; 13:902-14; PMID:11907271; http://dx.doi.org/10.1091/mbc.01-08-0398
26. Wilkes MC, Murphy SJ, Garamszegi N, Leof EB. Celltype-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Mol Cell Biol 2003; 23:8878-89; PMID:14612425; http://dx.doi.org/10.1128/MCB.23.23.8878-8889.2003
27. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005; 307:1603-9; PMID:15761148; http://dx.doi.org/10.1126/science.1105718
28. Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, et al. A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc Natl Acad Sci U S A 2009; 106:14028-33; PMID:19667198; http://dx.doi.org/10.1073/pnas.0906796106
29. Hough C, RaduM, Dore JJ. Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS One 2012; 7:e42513; PMID:22880011; http://dx.doi.org/10.1371/journal.pone.0042513
30. Yan X, Chen YG. Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling. Biochem J 2011; 434:1-10; PMID:21269274; http://dx.doi.org/10.1042/BJ20101827
31. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15:178-96; PMID:24556840; http://dx.doi.org/10.1038/nrm3758
32. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ. TGF-beta: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst 2014; 106:djt369; PMID:24511106
33. Wendt MK, Tian M, Schiemann WP. Deconstructing the mechanisms and consequences of TGF-betainduced EMT during cancer progression. Cell Tissue Res 2012; 347:85-101; PMID:21691718; http://dx.doi.org/10.1007/s00441-011-1199-1
34. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013; 13:788-99; PMID:24132110; http://dx.doi.org/10.1038/nrc3603
35. Verrecchia F, Mauviel A. Transforming growth factorbeta and fibrosis. World J Gastroenterol 2007; 13:3056-62; PMID:17589920
36. Mehner C, Radisky DC. Triggering the landslide: The tumor-promotional effects of myofibroblasts. Exp Cell Res 2013; PMID:23528452
37. Radisky DC, Bissell MJ. Matrix metalloproteinaseinduced genomic instability. Curr Opin Genet Dev 2006; 16:45-50; PMID:16377172; http://dx.doi.org/10.1016/j.gde.2005.12.011
38. Ungefroren H, Lenschow W, Chen WB, Faendrich F, Kalthoff H. Regulation of biglycan gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein Kinase signaling downstream of Smad signaling. J Biol Chem 2003; 278:11041-9; PMID:12538652; http://dx.doi.org/10.1074/jbc. M300035200
39. Verrecchia F, Mauviel A. Transforming growth factorbeta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002; 118:211-5; PMID:11841535; http://dx.doi.org/10.1046/j.1523-1747.2002.01641.x
40. Wang N, Wang X, Sun B, Zeng M, Xing C, Zhao X, Yang J. Role of TGF-beta1 in production of fibronectin in vascular smooth muscle cells cultured under highphosphate conditions. J Nephrol 2013; 26:213-8; PMID:22641576; http://dx.doi.org/10.5301/jn.5000127
41. Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC. Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med 2012; 4:142ra95; PMID:22786680; http://dx.doi.org/10.1126/scitranslmed. 3004062
42. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 2007; 67:10123-8; PMID:17974953; http://dx.doi.org/10.1158/0008-5472.CAN-07-3127
43. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 2007; 101:830-9; PMID:17211838; http://dx.doi.org/10.1002/jcb.21186
44. Li M, Krishnaveni MS, Li C, Zhou B, Xing Y, Banfalvi A, Lombardi V, Akbari O, Borok Z, Minoo P. Epithelium-specific deletion of TGF-beta receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J Clin Invest 2011; 121:277-87; PMID:21135509; http://dx.doi.org/10.1172/JCI42090
45. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, Bishop JM. MYC suppresses cancer metastasis by direct transcriptional silencing of alphav and beta3 integrin subunits. Nat Cell Biol 2012; 14:567-74; PMID:22581054; http://dx.doi.org/10.1038/ncb2491
46. Pechkovsky DV, Scaffidi AK, Hackett TL, Ballard J, Shaheen F, Thompson PJ, Thannickal VJ, Knight DA. Transforming growth factor beta1 induces alphavbeta3 integrin expression in human lung fibroblasts via a beta3 integrin-, c-Src-, and p38 MAPK-dependent pathway. J Biol Chem 2008; 283:12898-908; PMID:18353785; http://dx.doi.org/10.1074/jbc.M708226200
47. Yeh YC, Wei WC, Wang YK, Lin SC, Sung JM, Tang MJ. Transforming growth factor-{beta}1 induces Smad3-dependent {beta}1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. Am J Pathol 2010; 177:1743-54; PMID:20709799; http://dx.doi.org/10.2353/ajpath.2010.091183
48. Yeh YY, Chiao CC, Kuo WY, Hsiao YC, Chen YJ, Wei YY, Lai TH, Fong YC, Tang CH. TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells. Biochem Pharmacol 2008; 75:1292-301; PMID:18191107; http://dx.doi.org/10.1016/j.bcp.2007.11.017
49. Fransvea E, Mazzocca A, Antonaci S, Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009; 49:839-50; PMID:19115199; http://dx.doi.org/10.1002/hep.22731
50. Zhang YJ, Tian ZL, Yu XY, Zhao XX, Yao L. Activation of integrin beta1-focal adhesion kinase-RasGTP pathway plays a critical role in TGF beta1-induced podocyte injury. Cell Signal 2013; 25:2769-79; PMID:24036212; http://dx.doi.org/10.1016/j.cellsig.2013.08.044
51. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 2009; 69:475-82; PMID:19147560; http://dx.doi.org/10.1158/0008-5472.CAN-08-2649
52. Munger JS, Sheppard D. Cross talk among TGF-beta signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb Perspect Biol 2011; 3: a005017; PMID:21900405
53. Worthington JJ, Klementowicz JE, Travis MA. TGFbeta: a sleeping giant awoken by integrins. Trends Biochem Sci 2011; 36:47-54; PMID:20870411; http://dx.doi.org/10.1016/j.tibs.2010.08.002
54. Alcaraz LB, Exposito JY, Chuvin N, Pommier RM, Cluzel C, Martel S, Lai TH, Fong YC, Tang CH. Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-beta. J Cell Biol 2014; 205:409-28; PMID:24821840; http://dx.doi.org/10.1083/jcb.201308031
55. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SL. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 2002; 157:493-507; PMID:11970960; http://dx.doi.org/10.1083/jcb.200109100
56. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996; 10:1077-83; PMID:8885242
57. Buscemi L, Ramonet D, Klingberg F, Formey A, Smith-Clerc J, Meister JJ, Hinz B. The single-molecule mechanics of the latent TGF-beta1 complex. Curr Biol 2011; 21:2046-54; PMID:22169532; http://dx.doi.org/10.1016/j.cub.2011.11.037
58. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA. Latent TGF-beta structure and activation. Nature 2011; 474:343-9; PMID:21677751; http://dx.doi.org/10.1038/nature10152
59. Giacomini MM, Travis MA, KudoM, Sheppard D. Epithelial cells utilize cortical actin/myosin to activate latent TGF-beta through integrin alpha(v)beta(6)-dependent physical force. Exp Cell Res 2012; 318:716-22; PMID:22309779; http://dx.doi.org/10.1016/j.yexcr.2012.01.020
60. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998; 95:507-19; PMID:9827803; http://dx.doi.org/10.1016/S0092-8674(00)81618-9
61. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995; 121:1845-54; PMID:7600998
62. Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, Sung J, Xiong X, Munger JS. Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol 2007; 176:787-93; PMID:17353357; http://dx.doi.org/10.1083/jcb.200611044
63. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski PG, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013; 19:1617-24; PMID:24216753; http://dx.doi.org/10.1038/nm.3282
64. Hinz B. It has to be the alphav: myofibroblast integrins activate latent TGF-beta1. Nat Med 2013; 19:1567-8; PMID:24309651; http://dx.doi.org/10.1038/nm.3421
65. Mamuya FA, Duncan MK. aV integrins and TGFbeta-induced EMT: a circle of regulation. J Cell Mol Med 2012; 16:445-55; PMID:21883891; http://dx.doi.org/10.1111/j.1582-4934.2011.01419.x
66. Henderson NC, Sheppard D. Integrin-mediated regulation of TGFbeta in fibrosis. Biochim Biophys Acta 2013; 1832:891-6; PMID:23046811; http://dx.doi.org/10.1016/j.bbadis.2012.10.005
67. Serrano I, McDonald PC, Lock FE, Dedhar S. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFbeta-1-induced epithelial-mesenchymal transition (EMT). Oncogene 2013; 32:50-60; PMID:22310280; http://dx.doi.org/10.1038/onc.2012.30
68. Truong HH, Xiong J, Ghotra VP, Nirmala E, Haazen L, Le Devedec SE, Balcioglu HE, He S, Snaar-Jagalska BE, Vreugdenhil E, et al. beta1 integrin inhibition elicits a prometastatic switch through the TGFbeta-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Sci Signal 2014; 7:ra15; PMID:24518294
69. Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML, Frank JA, Brumwell AN, Wheeler SE, Kreidberg JA, et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 2009; 119:213-24; PMID:19104148
70. Chen X, Wang H, Liao HJ, Hu W, Gewin L, Mernaugh G, Zhang S, Zhang ZY, Vega-Montoto L, Vanacore RM, et al. Integrin-mediated type II TGF-beta receptor tyrosine dephosphorylation controls SMADdependent profibrotic signaling. J Clin Invest 2014; 124:3295-310; PMID:24983314
71. Vi L, de Lasa C, DiGuglielmo GM, Dagnino L. Integrin-linked kinase is required for TGF-beta1 induction of dermal myofibroblast differentiation. J Invest Dermatol 2011; 131:586-93; PMID:21150927; http://dx.doi.org/10.1038/jid.2010.362
72. Asano Y, Ihn H, Jinnin M, Mimura Y, Tamaki K. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 2006; 126:1761-9; PMID:16675963; http://dx.doi.org/10.1038/sj.jid.5700331
73. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006; 168:499-510; PMID:16436664; http://dx.doi.org/10.2353/ajpath.2006.041306
74. Scaffidi AK, Petrovic N, Moodley YP, Fogel-Petrovic M, Kroeger KM, Seeber RM, Eidne KA, Thompson PJ, Knight DA. alpha(v)beta(3) Integrin interacts with the transforming growth factor beta (TGFbeta) type II receptor to potentiate the proliferative effects of TGFbeta1 in living human lung fibroblasts. J Biol Chem 2004; 279:37726-33; PMID:15187087; http://dx.doi.org/10.1074/jbc.M403010200
75. Galliher AJ, Schiemann WP. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 2006; 8:R42; PMID:16859511; http://dx.doi.org/10.1186/bcr1524
76. Parvani JG, Galliher-Beckley AJ, Schiemann BJ, Schiemann WP. Targeted inactivation of beta1 integrin induces beta3 integrin switching, which drives breast cancer metastasis by TGF-beta. Mol Biol Cell 2013; 24:3449-59; PMID:24006485; http://dx.doi.org/10.1091/mbc.E12-10-0776
77. Garamszegi N, Garamszegi SP, Samavarchi-Tehrani P, Walford E, Schneiderbauer MM, Wrana JL, Scully SP. Extracellular matrix-induced transforming growth factor-beta receptor signaling dynamics. Oncogene 2010; 29:2368-80; PMID:20101206; http://dx.doi.org/10.1038/onc.2009.514
78. Wendt MK, Schiemann WP. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGFbeta signaling and metastasis. Breast Cancer Res 2009; 11:R68; PMID:19740433; http://dx.doi.org/10.1186/bcr2360
79. Reynolds LE, Conti FJ, Lucas M, Grose R, Robinson S, Stone M, Saunders G, Dickson C, Hynes RO, Lacy-Hulbert A, et al. Accelerated re-epithelialization in beta3-integrin-deficient-mice is associated with enhanced TGF-beta1 signaling. Nat Med 2005; 11:167-74; PMID:15654327; http://dx.doi.org/10.1038/nm1165
80. Wang D, Sun L, Zborowska E, Willson JK, Gong J, Verraraghavan J, Brattain MG. Control of type II transforming growth factor-beta receptor expression by integrin ligation. J Biol Chem 1999; 274:12840-7; PMID:10212271; http://dx.doi.org/10.1074/jbc.274.18.12840
81. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 2012; 11:790-811; PMID:23000686; http://dx.doi.org/10.1038/nrd3810
82. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3:1011-22; PMID:15573100; http://dx.doi.org/10.1038/nrd1580
83. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13:132-42; PMID:20980335; http://dx.doi.org/10.1093/neuonc/noq142
84. Oettle H, Seufferlein T. Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. J Clin Oncol. 2011; 29:abstract 2513
85. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012; 8:964-78; PMID:22811618; http://dx.doi.org/10.7150/ijbs.4564
86. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 9:804-20; PMID:20885411; http://dx.doi.org/10.1038/nrd3266
87. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012; 33:405-12; PMID:22633092; http://dx.doi.org/10.1016/j.tips.2012.04. 002
88. Ning S, Tian J, Marshall DJ, Knox SJ. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res 2010; 70:7591-9; PMID:20841470; http://dx.doi.org/10.1158/0008-5472.CAN-10-1639
89. O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, et al. A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 2011; 105:346-52; PMID:21750555; http://dx.doi.org/10.1038/bjc.2011.183